Patents by Inventor Boris Zemelman

Boris Zemelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11174495
    Abstract: The present invention provides methods and compositions for labeling and/or targeting cells with increased calcium by providing a CREB reporter system. In addition, methods of treating disorders with activated cells such as brain disorders or cancer are also provided herein.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: November 16, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Boris Zemelman
  • Publication number: 20180363003
    Abstract: The present invention provides methods and compositions for labeling and/or targeting cells with increased calcium by providing a CREB reporter system. In addition, methods of treating disorders with activated cells such as brain disorders or cancer are also provided herein.
    Type: Application
    Filed: December 5, 2016
    Publication date: December 20, 2018
    Inventor: Boris ZEMELMAN
  • Patent number: 7883846
    Abstract: Methods and compositions to activate a genetically designated target cell (or population of target cells) artificially, in vivo or in vitro, employ triggering of heterologous stimulus-gated ion channels to activate the cells. The stimulus-gated ion channels are suitably TRPV1, TRPM8 or P2X2. A stimulus which leads to opening or “gating” of the ion channel can be a physical stimulus or a chemical stimulus. Physical stimuli can be provided by heat, or mechanical force, while chemical stimuli can suitably be a ligand, such as capsaicin for TRPV1 or ATP for P2X2, or a “caged ligand,” for example a photolabile ligand derivative, in which case a physical signal in the form of light is used to provide the chemical signal. Selective activation of the cell may be used for various applications including neuronal and neuroendocrine mapping and drug screening.
    Type: Grant
    Filed: June 2, 2003
    Date of Patent: February 8, 2011
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Gero Miesenbock, Boris Zemelman